Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer [scRNA-seq]

ABSTRACT: Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer [scRNA-seq]

PROVIDER: PRJNA981496 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24877169.fastq.gz	Fastqsanger.gz
	SRR24877170.fastq.gz	Fastqsanger.gz
	SRR24877171.fastq.gz	Fastqsanger.gz
	SRR24877172.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer.

Project description:Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer.

| PRJNA981495 | ENA

Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer

Project description:Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer

| PRJNA981494 | ENA

Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer.

Project description:We performed bulk-RNA sequencing analysis from KRAS G12V mouse tumor nodules from different treatment.

2024-12-18 | GSE234470 | GEO

Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer [scRNA-seq]

Project description:We performed single cell RNA sequencing analysis from KRAS G12V mouse tumor nodules from different treatment.

2024-12-18 | GSE234471 | GEO

Oncogenic KRAS(G12V) and BRAF(V600E) in intestinal organoids

Project description:Goals of the study was to compare transcripional and phenotypic response of mouse intestinal organoid cultures to the KRAS(G12V) or BRAF(V600E)oncogenes.

2018-06-02 | GSE115234 | GEO

KRAS mutation (G12V) expression by pBABE-Puro vector in NCI-H1703 cells

Project description:The goal of this study was to determine genes affected by expressing KRAS mutation (G12V) in NCI-H1703 cells This data was used in Meng Wang et. al. Cancer Research 2016 to determine the alterations of gene expression profiling associated with expression of KRAS mutation (G12V). The experiment uses a pBABE-Puro vector encoding KRAS G12V and a corresponding empty vector control.

2016-03-23 | E-GEOD-79486 | biostudies-arrayexpress

Murine lung tumors- HER2(V659E) and KRAS(G12V) vs normal lung

Project description:Transcriptiional profling of 13 normal lung samples, 18 lung KRAS(G12V) tumor samples, and 18 lung HER2(V659E) tumor samples 13 normal lung samples, 18 lung KRAS(G12V) tumor samples, and 18 lung HER2(V659E) tumor samples hybridized against Stratagene universal mouse reference RNA with dye swap

2009-11-30 | E-GEOD-18784 | biostudies-arrayexpress

Targeted degradation of oncogenic KRAS G12V triggers antitumor immunity in lung cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2024-12-18 | GSE234472 | GEO

Transcriptional effects of a first-in-class EGFR-directed KRAS G12V selective inhibitor, EFTX-G12V, on H727 cells.

Project description:Despite KRAS-G12V being the second most common KRAS mutation in cancer, there are no approved direct KRAS-G12V inhibitors. Difficulties with inhibiting oncogenes using conventional approaches have prompted the use of RNAi as a therapeutic approach. RNAi has faced numerous obstacles as a cancer therapeutic, including the lack of cancer-specific tissue targeting, rapid oligonucleotide nuclease degradation and clearance from the circulation. Recently, the use of targetable ligands conjugated to chemically modified siRNAs has shown remarkable promise in circumventing these barriers. We demonstrate that EFTX-G12V is highly selective for KRAS-G12V and has improved therapeutic activity over pan-KRAS targeting, including enhanced inhibition of several cancer hallmarks. With a novel RNAi delivery platform, we demonstrate tumor silencing of KRAS-G12V and significant anti-tumor activity across several cancer models. Our findings represent a technologic advance in oncogene targeting using RNAi and reveal new biologic insights in KRAS targeting that may have broad implications with regards to safety and efficacy. This dataset collects the RNA-Seq data for the H727 cell line.

2025-07-16 | GSE278019 | GEO

Transcriptional effects of a first-in-class EGFR-directed KRAS G12V selective inhibitor, EFTX-G12V, on H441 cells.

2025-07-16 | GSE278018 | GEO